Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix Announces Proposed Acquisition of QSAM Biosciences
- First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study
- Telix Completes Acquisition of Lightpoint Medical
- ProstACT SELECT Study of TLX591 Positive Interim Readout
- Q3 2023 Business Update to Accompany Quarterly Results
Later from Telix Pharmaceuticals
- Telix Plans U.S. Registered Public Offering and Listing
- JP Morgan Healthcare Conference and Trading Update
- JP Morgan Healthcare Conference Presentation
- Presentation to Accompany QSAM Acquisition
- Telix Acquires QSAM and its Bone Cancer Targeting Platform
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals